Cargando…
Secretory phospholipase A2 in SARS-CoV-2 infection and multisystem inflammatory syndrome in children (MIS-C)
Secretory phospholipase 2 (sPLA2) acts as a mediator between proximal and distal events of the inflammatory cascade. Its role in SARS-CoV-2 infection is unknown, but could contribute to COVID-19 inflammasome activation and cellular damage. We present the first report of plasma sPLA2 levels in adults...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8649422/ https://www.ncbi.nlm.nih.gov/pubmed/34255566 http://dx.doi.org/10.1177/15353702211028560 |
_version_ | 1784610992483729408 |
---|---|
author | Kuypers, Frans A Rostad, Christina A Anderson, Evan J Chahroudi, Ann Jaggi, Preeti Wrammert, Jens Mantus, Grace Basu, Rajit Harris, Frank Hanberry, Bradley Camacho-Gonzalez, Andres Manoranjithan, Shaminy Vos, Miriam Brown, Lou Ann Morris, Claudia R |
author_facet | Kuypers, Frans A Rostad, Christina A Anderson, Evan J Chahroudi, Ann Jaggi, Preeti Wrammert, Jens Mantus, Grace Basu, Rajit Harris, Frank Hanberry, Bradley Camacho-Gonzalez, Andres Manoranjithan, Shaminy Vos, Miriam Brown, Lou Ann Morris, Claudia R |
author_sort | Kuypers, Frans A |
collection | PubMed |
description | Secretory phospholipase 2 (sPLA2) acts as a mediator between proximal and distal events of the inflammatory cascade. Its role in SARS-CoV-2 infection is unknown, but could contribute to COVID-19 inflammasome activation and cellular damage. We present the first report of plasma sPLA2 levels in adults and children with COVID-19 compared with controls. Currently asymptomatic adults with a history of recent COVID-19 infection (≥4 weeks before) identified by SARS-CoV-2 IgG antibodies had sPLA2 levels similar to those who were seronegative (9 ± 6 vs.17 ± 28 ng/mL, P = 0.26). In contrast, children hospitalized with severe COVID-19 had significantly elevated sPLA2 compared with those with mild or asymptomatic SARS-CoV-2 infection (269 ± 137 vs. 2 ± 3 ng/mL, P = 0.01). Among children hospitalized with multisystem inflammatory syndrome in children (MIS-C), all had severe disease requiring pediatric intensive care unit (PICU) admission. sPLA2 levels were significantly higher in those with acute illness <10 days versus convalescent disease ≥10 days (540 ± 510 vs. 2 ± 1, P = 0.04). Thus, sPLA2 levels correlated with COVID-19 severity and acute MIS-C in children, implicating a role in inflammasome activation and disease pathogenesis. sPLA2 may be a useful biomarker to stratify risk and guide patient management for children with acute COVID-19 and MIS-C. Therapeutic compounds targeting sPLA2 and inflammasome activation warrant consideration. |
format | Online Article Text |
id | pubmed-8649422 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-86494222021-12-08 Secretory phospholipase A2 in SARS-CoV-2 infection and multisystem inflammatory syndrome in children (MIS-C) Kuypers, Frans A Rostad, Christina A Anderson, Evan J Chahroudi, Ann Jaggi, Preeti Wrammert, Jens Mantus, Grace Basu, Rajit Harris, Frank Hanberry, Bradley Camacho-Gonzalez, Andres Manoranjithan, Shaminy Vos, Miriam Brown, Lou Ann Morris, Claudia R Exp Biol Med (Maywood) Original Research Secretory phospholipase 2 (sPLA2) acts as a mediator between proximal and distal events of the inflammatory cascade. Its role in SARS-CoV-2 infection is unknown, but could contribute to COVID-19 inflammasome activation and cellular damage. We present the first report of plasma sPLA2 levels in adults and children with COVID-19 compared with controls. Currently asymptomatic adults with a history of recent COVID-19 infection (≥4 weeks before) identified by SARS-CoV-2 IgG antibodies had sPLA2 levels similar to those who were seronegative (9 ± 6 vs.17 ± 28 ng/mL, P = 0.26). In contrast, children hospitalized with severe COVID-19 had significantly elevated sPLA2 compared with those with mild or asymptomatic SARS-CoV-2 infection (269 ± 137 vs. 2 ± 3 ng/mL, P = 0.01). Among children hospitalized with multisystem inflammatory syndrome in children (MIS-C), all had severe disease requiring pediatric intensive care unit (PICU) admission. sPLA2 levels were significantly higher in those with acute illness <10 days versus convalescent disease ≥10 days (540 ± 510 vs. 2 ± 1, P = 0.04). Thus, sPLA2 levels correlated with COVID-19 severity and acute MIS-C in children, implicating a role in inflammasome activation and disease pathogenesis. sPLA2 may be a useful biomarker to stratify risk and guide patient management for children with acute COVID-19 and MIS-C. Therapeutic compounds targeting sPLA2 and inflammasome activation warrant consideration. SAGE Publications 2021-07-13 2021-12 /pmc/articles/PMC8649422/ /pubmed/34255566 http://dx.doi.org/10.1177/15353702211028560 Text en © 2021 by the Society for Experimental Biology and Medicine https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Research Kuypers, Frans A Rostad, Christina A Anderson, Evan J Chahroudi, Ann Jaggi, Preeti Wrammert, Jens Mantus, Grace Basu, Rajit Harris, Frank Hanberry, Bradley Camacho-Gonzalez, Andres Manoranjithan, Shaminy Vos, Miriam Brown, Lou Ann Morris, Claudia R Secretory phospholipase A2 in SARS-CoV-2 infection and multisystem inflammatory syndrome in children (MIS-C) |
title | Secretory phospholipase A2 in SARS-CoV-2 infection and multisystem inflammatory syndrome in children (MIS-C) |
title_full | Secretory phospholipase A2 in SARS-CoV-2 infection and multisystem inflammatory syndrome in children (MIS-C) |
title_fullStr | Secretory phospholipase A2 in SARS-CoV-2 infection and multisystem inflammatory syndrome in children (MIS-C) |
title_full_unstemmed | Secretory phospholipase A2 in SARS-CoV-2 infection and multisystem inflammatory syndrome in children (MIS-C) |
title_short | Secretory phospholipase A2 in SARS-CoV-2 infection and multisystem inflammatory syndrome in children (MIS-C) |
title_sort | secretory phospholipase a2 in sars-cov-2 infection and multisystem inflammatory syndrome in children (mis-c) |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8649422/ https://www.ncbi.nlm.nih.gov/pubmed/34255566 http://dx.doi.org/10.1177/15353702211028560 |
work_keys_str_mv | AT kuypersfransa secretoryphospholipasea2insarscov2infectionandmultisysteminflammatorysyndromeinchildrenmisc AT rostadchristinaa secretoryphospholipasea2insarscov2infectionandmultisysteminflammatorysyndromeinchildrenmisc AT andersonevanj secretoryphospholipasea2insarscov2infectionandmultisysteminflammatorysyndromeinchildrenmisc AT chahroudiann secretoryphospholipasea2insarscov2infectionandmultisysteminflammatorysyndromeinchildrenmisc AT jaggipreeti secretoryphospholipasea2insarscov2infectionandmultisysteminflammatorysyndromeinchildrenmisc AT wrammertjens secretoryphospholipasea2insarscov2infectionandmultisysteminflammatorysyndromeinchildrenmisc AT mantusgrace secretoryphospholipasea2insarscov2infectionandmultisysteminflammatorysyndromeinchildrenmisc AT basurajit secretoryphospholipasea2insarscov2infectionandmultisysteminflammatorysyndromeinchildrenmisc AT harrisfrank secretoryphospholipasea2insarscov2infectionandmultisysteminflammatorysyndromeinchildrenmisc AT hanberrybradley secretoryphospholipasea2insarscov2infectionandmultisysteminflammatorysyndromeinchildrenmisc AT camachogonzalezandres secretoryphospholipasea2insarscov2infectionandmultisysteminflammatorysyndromeinchildrenmisc AT manoranjithanshaminy secretoryphospholipasea2insarscov2infectionandmultisysteminflammatorysyndromeinchildrenmisc AT vosmiriam secretoryphospholipasea2insarscov2infectionandmultisysteminflammatorysyndromeinchildrenmisc AT brownlouann secretoryphospholipasea2insarscov2infectionandmultisysteminflammatorysyndromeinchildrenmisc AT morrisclaudiar secretoryphospholipasea2insarscov2infectionandmultisysteminflammatorysyndromeinchildrenmisc |